Pidotimod in the treatment of pediatric recurrent respiratory tract infection

Abstract

Objective: To observe the clinical efficacy of pidotimod in the treatment of recurrent respiratory tract infection in children.
 Methods: One hundred thirty-two patients with recurrent respiratory tract infection who received treatment in Tianan City Central Hospital were selected and divided into an observation group and a control group using random number table, 66 in each group. Patients in the control group were given conventional treatment, while patients in the observation group were given conventional treatment and pidotimod treatment; the clinical efficacy of the two therapies was compared. The levels of IgG and IgM were measured after treatment.
 Results: The vital signs and the content of inflammatory mediator and Th1/Th2 in serum before and after treatment were compared, and the clinical efficacy of the two groups was evaluated. The fever, pulmonary rale, cough and antiadoncus of patients in the observation group disappeared earlier than those in the control group (P<0.05). The onset duration of respiratory tract infection and days of antibiotic application of the observation group were shorter than those of the control group after treatment (P<0.05). The times of infection of the observation group were less than that of the control group (P<0.05). Before treatment, the two groups had no significant difference in the content of inflammatory mediators and Th1/Th2 in the serum (P>0.05). The serum content of tumor necrosis factor (TNF)-α and interleukin (IL)-4 of the two groups one week after treatment was lower than that before treatment, and the content of interferon (IFN)-γ and IFN-γ/IL-4 were higher than that before treatment; moreover the observation group had lower serum content of TFN-α and IL-4 and lower content of IFN-γ and IFN-γ/IL-4 compared to the control group (P<0.05). The overall response rate of the observation group was 92.4%, much higher than 81.8% in the control group (P<0.05).
 Conclusion: Pidotimod has a remarkable efficacy in the treatment of pediatric recurrent respiratory tract infection because it can effectively inhibit the infection and optimize Th1/Th2 immune function.
 doi: https://doi.org/10.12669/pjms.35.4.82
 How to cite this:Li X, Li Q, Wang X, Lu M, Shen J, Meng Q. Pidotimod in the treatment of pediatric recurrent respiratory tract infection. Pak J Med Sci. 2019;35(4):---------. doi: https://doi.org/10.12669/pjms.35.4.82
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Efficacy of five different traditional Chinese medicine injections in acute upper respiratory tract infection in children: a network meta-analysis and systematic review

“…Twenty-eight RCTs ( 22 – 24 , 26 , 28 , 34 , 35 , 47 , 49 , 50 , 52 , 65 – 69 , 71 – 75 , 79 , 80 , 86 , 88 , 90 , 95 , 97 , 101 ) reported the safety of TCMIs and specific adverse reactions, including diarrhea, vomiting, rash at the injection site, loss of appetite, allergies, abdominal pain, laryngitis, and headache. Only a descriptive analysis was performed because the descriptive criteria in the various studies were not uniform.…”

“…Diarrhea and allergic reactions are the most common adverse effects of using TCMIs. Twenty-eight RCTs included in this review described TCMIs as having mild adverse effects ( 22 – 24 , 26 , 28 , 34 , 35 , 47 , 49 , 50 , 52 , 65 – 69 , 71 – 75 , 79 , 80 , 86 , 88 , 90 , 95 , 97 , 101 ), which could be mitigated or eliminated by discontinuing the medication, decreasing the dose of the medication, or symptomatic treatment. The safety of TCMIs is greatly improved by standardizing their use in clinical applications ( 132 ).…”

Mycoplasma pneumoniae and Recurrent Respiratory Tract Infection Within One Year After Treatment in Infants: Risk Factors and Prevalence

“…The prevalence was similar in MP RRTIs and viral RRTIs. At present, the pathogenesis of pediatric RRTIs is not clear, although it has been reported that it may be associated with congenital factors (such as underlying respiratory or cardiovascular disease), immunosuppression, and deficiency of trace elements (19). Therefore, the exclusion of patients with underlying diseases can improve the identification of readmission risk factors associated with RRTIs in infants in their first year of life who have been clinically treated for MPP (20).…”